<DOC>
	<DOC>NCT02888054</DOC>
	<brief_summary>This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects</brief_summary>
	<brief_title>Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence</brief_title>
	<detailed_description>The study will assess the BE between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fed state.</detailed_description>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject has a body mass index ranging between 18 kg/m2 and 30 kg/m2. Screening serum urate level is â‰¤ 7.0 mg/dL. Asian subject who has a positive test for the HLAB*5801 allele. History or suspicion of kidney stones. Estimated creatinine clearance, as determined at Screening, of &lt; 90 mL/min calculated by the CockcroftGault formula using ideal body weight. Undergone major surgery within 3 months prior to Screening. Donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior to Day 1or has given a plasma donation within 4 weeks prior to Day 1. Inadequate venous access or unsuitable veins for repeated venipuncture. Received any strong or moderate enzymeinducing drug or product within 2 months prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>